Toshiyuki Tamai

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Masatoshi Kudo, Richard S. Finn, Shukui Qin et al. · The Lancet · 2018 · 5.4K citations · Full text

Medicine, Oncology, Pharmacology +12

Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma

Kenji Ikeda, Masatoshi Kudo, Seiji Kawazoe et al. · Journal of Gastroenterology · 2016 · 344 citations · Full text

Medicine, Oncology, Pharmacology +15

REFLECT—a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset

Tatsuya Yamashita, Masatoshi Kudo, Kenji Ikeda et al. · Journal of Gastroenterology · 2019 · 227 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma

Masafumi Ikeda, Takuji Okusaka, Shuichi Mitsunaga et al. · Clinical Cancer Research · 2015 · 189 citations

Pharmacy, Clinical Pharmacokinetics, Pharmacology +16

Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial

Arndt Vogel, Shukui Qin, Masatoshi Kudo et al. · ˜The œLancet. Gastroenterology & hepatology · 2021 · 153 citations

Medicine, Oncology, Pharmacotherapy +12